Coronary heart disease (CHD) is the leading cause of death in the United States.1 High level of cholesterol in the blood (hypercholesterolaemia) is one of the major contributors to atherosclerosis and coronary heart disease. 2 Serum cholesterol is an important determinant of cardiovascular (CV) risk. The increased risk is due mainly to raised low-density lipoprotein cholesterol (LDL-C). 3  Lowering the concentration of LDL-C has been proved to reduce the risk of CV events, morbidity and mortality. 3 The new lipid-lowering agents with an improved efficacy and a low potential for adverse effects may contribute to efforts to address this public health issue. 4

HS-25 Description

Hisun is developing HS-25, a novel investigational orally administered drug product for the treatment of primary hypercholesterolaemia. HS-25 is designed for use as monotherapy and as combination therapy with HMG-CoA reductase inhibitors (Statins) for the treatment of primary hypercholesterolemia.

Hisun is actively seeking to:

  • Identify a co-development partner
  • Out-license regional rights
  • Out-license world-wide rights

For more information, please contact:
Peggy Albanese
Director Business Development and Sales
Hisun Pharmaceuticals USA, Inc.
212 Carnegie Center, Suite 302
Princeton, NJ 08540-6236
Office: 609-454-0237
Email: Peggy.Albanese@hisunusa.com


  1. Morbidity and Mortality Weekly Report (MMWR). Available at:  http://www.cdc.gov/mmwr/preview/mmwrhtml/su6203a26.htm  Accessed November 17, 2016.
  2. Nelson H, Robert. Hyperlipidemia as a Risk Factor for Cardiovascular Disease.Prim Care. 2013 Mar:40(1). 195-211.
  3. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Available athttp://circ.ahajournals.org/content/110/2/227.  Accessed November 17, 2016
  4. Sampson K, Uchevhukwu et al. Residual Cardiovascular Risk Despite Optimal LDL-Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. Curr Atheroscler Rep. 2012 Feb; 14(1): 1–10.